Perrigo, a leading provider of quality, affordable self-care products announced that it has received final approval from the U.S. Food and Drug Administration for the over-the-counter use of Nasonex, a (mometasone furoate monohydrate 50mcg). This approval marks the first branded Rx-to-OTC switch for the company and paves the way for Nasonex to enter the OTC marketplace. Perrigo expects to begin offering Nasonex later this year.

Perrigo Executive Vice President & President, Consumer Self-Care Americas, Jim Dillard commented, "This first Rx-to-OTC switch for Nasonex represents our continued focus on providing quality, affordable self-care products that consumers know and trust. It also epitomizes the strength of our internal innovation, R&D and regulatory capabilities. Successfully bringing Rx-to-OTC switches to market expands offerings available to consumers, enhances offerings for our retail partners and continues to differentiate Perrigo in the marketplace."

Nasonex is a registered trademark of Organon and is used by Perrigo and its affiliates under license.